Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus chemotherapy as neoadjuvant therapy for stage III-IV endometrial cancer
ChiCTR2600132330Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in endometrial cancer (EC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Total pathological complete response rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on ChiCTR2600132330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132330.